The UF BRAIN Center mission is to improve understanding of neuroresilience and neural injury and its difference from other neurological diseases, while developing new diagnostic and therapeutic strategies to treat traumatic or anoxic neural injury.
Brooks Rehabilitation has served patients across 23 counties in North Florida for nearly 50 years. Its services help promote, maintain and restore health while minimizing the effects of illness and disability.
The goal of the Center for Spatial Biomolecule Research (CASBR) is to leverage spatial metabolomics expertise and transdisciplinary approaches to help UF researchers uncover molecular, metabolic, and cellular underpinnings of biology, physiology, and disease pathology. CASBR provides high-throughput, well-validated spatial biomolecular services and serves as the nucleating center for multidisciplinary collaboration from diverse research across campus in all research areas that involve spatial biology.
The Center for Movement Disorders & Neurorestoration is founded on the philosophy that integrated, interdisciplinary care is the most effective approach for patients with movement disorders and disorders involving a group of circuits in the brain called the basal ganglia. It delivers motor, cognitive and behavioral diagnoses as well as various treatments all in one centralized location.
The Center for NeuroGenetics (CNG) integrates molecular, genetic and clinical approaches to define the causes of neurodegenerative disease and develops effective treatment strategies.
The Center for Translational Research in Neurodegenerative Disease is a state of the art, multi-disciplinary research center focused on the discovery, development and evaluation of future treatments and diagnostics for degenerative central nervous system conditions including Alzheimer’s disease, Amyotrophic Lateral Sclerosis, Frontotemporal Lobar Degeneration, Parkinson’s disease, and Stroke.
The UF Clinical and Translational Science Institute (CTSI) was founded in 2008 and it is dedicated to improve human health by accelerating the translation of scientific discoveries and the implementation of evidence-based best practices for the diagnosis, treatment, prevention and cure of human disease.
Inaugurated during the COVID-19 pandemic, the International Online Spinal Cord Injury Research Seminars (IOSCIRS) host experts in the field of spinal cord injury. With seminars broadcast on YouTube, they have developed a robust seminar series that touches on issues of interest to the broader spinal cord research injury community, including neurotrauma, neuroscience, repair, regeneration, walking, and paralysis. We are pleased to be part of the IOSCIRS network!
The MBI building houses the four “neuro” departments of the UF College of Medicine: neurology, neurosurgery, neuroscience and psychiatry. All four of these departments have major investments and research in the neurosciences and neuromedicine.
The UF Myology Institute brings researchers from throughout UF campus, private industry, and other institutions together in a collaborative effort to further the understanding and treatment of neuromuscular diseases.
The Nanoscience Institute for Medical and Engineering Technology (NIMET) is a university-wide institute administered by the Herbert Wertheim College of Engineering. Research in fields that study, engineer, or apply nanoscale breakthroughs at UF has grown in multiple disciplines across the entire campus and now involves over 280 faculty and staff in physics, chemistry, biology, medicine, engineering, food/agricultural sciences, and more.
The Norman Fixel Institute for Neurological Diseases is home to scientists and clinicians at UF Health who are working on neurological disorders that afflict millions of people across the globe. These conditions include Parkinson’s, dystonia and other movement disorders, Alzheimer’s disease and dementias, concussion, traumatic brain injury, and neuromuscular disorders like Amyotrophic Lateral Sclerosis, also known as ALS, or Lou Gehrig’s disease.
The Powell Gene Therapy Center (PGTC) at the University of Florida has been instrumental in the development of newer, safer agents for the delivery of therapeutic genes to patients with genetic diseases, such as cystic fibrosis (CF) and alpha 1-antitrypsin deficiency (AAT-D).